In a Substack newsletter, Dr. William Makis cited a paper from 2020 (by Juarez et al) on the antitumor effects of ivermectin at clinically feasible concentrations where it was found to support its clinical development as a repositioned cancer drug.
According to the study, at a human dose of two mg/kg, ivermectin can achieve anti-cancer effects such as cell cycle arrest (inhibit proliferation), preferential inhibition of cancer stem-like cells, synergize with several chemotherapy drugs and inhibit tumor growth in a breast cancer mouse model.
Ivermectin was tested at two mg/kg/day, translating to roughly 5uM in vitro concentration. They found that the drug goes after cancer stem cells, which tend to be resistant to chemotherapy.
"Ivermectin has a preferential depletion effect on the cancer stem-like cell population," the authors included in the research. "We observed that among all the evaluated cell lines, a decrease in cell viability and clonogenicity is more evident in the cancer stem-like cells than in their parental population."
It also found that the most sensitive cancer cell lines were the ovarian, breast, glioblastoma (brain), lung, colon, uterine squamous cell carcinoma (SCC), hepatocellular, triple-negative breast cancer (TNBC), pancreatic and endometrial.
Meanwhile, the least sensitive were osteosarcoma, gastric and melanoma.
Moreover, lymphoma and leukemia cell lines appear to be more resistant to Ivermectin but the drug has a significant impact on those cells' ability to form colonies, according to the study. (Related: Ivermectin can "kill cancer cells" and boost immune response, suggest health experts.)
Makis further highlighted that this was the first study he had ever seen that had tested as many as 28 cancer types with ivermectin.
"No wonder it's hidden from the public," he commented.
NEW ARTICLE: IVERMECTIN Tested against 28 types of Cancer - which cancers were most sensitive to Ivermectin? Which were least sensitive?
A research group from Mexico investigated Ivermectin in Cancer
Paper: 2020 (Juarez et al) - Antitumor effects of ivermectin at clinically… pic.twitter.com/xWhgEBa1uv
— William Makis MD (@MakisMD) August 26, 2024
FDA took down social media posts discouraging ivermectin use for COVID-19 but mainstream media seemed to have missed this
Back in March, the U.S. Food and Drug Administration (FDA) agreed to permanently take down its social media posts urging people to avoid the usage of ivermectin for COVID-19.
One of the pages that the agency has removed was a page that said: "Should I take ivermectin to prevent or treat COVID-19? No." It also took down posts, including one that reads: "You are not a horse. You are not a cow. Seriously, y'all. Stop it."
The move was done following a lawsuit with a settlement filed with a federal court in Texas that ordered the agency to delete another page titled "Why you should not use ivermectin to treat or prevent COVID-19 within 21 days."
The article said that ivermectin was neither authorized nor approved to be used to prevent or treat COVID-19 in humans or animals. It also claims that evidence does not support the efficacy of ivermectin against coronavirus.
On June 2, 2022, Doctors Paul Marik, Mary Talley Bowden and Robert Apter filed a lawsuit against the FDA and its secretary Robert Califf, as well as the Department of Health and Human Services and its secretary Xavier Becerra. They accused the FDA of meddling with their capacity to practice medicine. The lawsuit was first turned down on the basis that the FDA has "sovereign immunity." However, the U.S. Court of Appeals for the Fifth Circuit overruled the lower court's ruling, stating that the "FDA is not a physician" and "even tweet-sized doses of personalized medical advice are beyond the FDA's statutory authority."
Ivermectin has long been approved for use in both animals and humans. In cases of humans, the drug is recommended to treat parasitic infections such as river blindness disease, threadworm infestation, tropical eosinophilia, roundworm infestation, whipworm infestation, filariasis (also called elephantiasis) and loiasis.
On X, formerly Twitter, Dr. Mary Talley Bowden wrote: "This landmark case sets an important precedent in limiting FDA overreach into the doctor-patient relationship."
Moreover, independent presidential candidate Robert F. Kennedy Jr in a tweet said: "The FDA is biased against many low-cost, generic, and/or natural therapies with low-profit potential. Could it be because half its funding comes from Big Pharma?"
Ivermectin is not an exceptional case. The FDA is biased against many low-cost, generic, and/or natural therapies with low profit potential. Could it be because half its funding comes from Big Pharma? https://t.co/LxpqLuvb6A
— Robert F. Kennedy Jr (@RobertKennedyJr) March 22, 2024
Australian politician Craig Kelly also called the FDA "corrupt," stating that they have "blood on their hands."
Head over to Cancer.news for more stories, similar to this.
Sources for this article include:
Please contact us for more information.
